Dr. Michael Henderson is the CEO of Apogee Therapeutics. He also serves on the company’s board of directors and is a member of the board of managers. He is an experienced biotechnology executive with expertise in business leadership, drug development, and commercial strategy, having overseen the creation of multiple companies, launched a significant number of drug development programs, and led teams to two FDA approvals, to date.

Prior to joining Apogee, Dr. Henderson served as Chief Business Officer of BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, where he was responsible for furthering the overarching strategy of BridgeBio, identifying and investing in new technologies, and running business development and operations. Dr. Henderson also served in leadership positions for several prominent subsidiary companies of BridgeBio.

Prior to BridgeBio, Dr. Henderson worked at McKinsey & Company, before which he co-founded PellePharm, Inc., a biotechnology company. Dr. Henderson has served on the board of directors of ARYA Sciences Acquisition Corp IV, a special purpose acquisition company focused on the healthcare industry, since February 2021. Dr. Henderson received his B.A. in global health from Harvard University and his M.D. from Stanford University.